Equillium’s Itolizumab Goes Toe-to-Toe With Humira in Ulcerative Colitis

In a mid-stage study, the candidate itolizumab achieved 23.3% clinical remission rate at 12 weeks, numerically better than Humira’s 20% at the same time point.